Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report
Name of Journal: World Journal of Gastroenterology
ESPS Manuscript NO: 3785
Title: 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via down-regulation of β-catenin
Reviewer code: 02441335
Science editor: Wen, Ling-Ling
Date sent for review: 2013-05-23 20:42
Date reviewed: 2013-05-27 20:07

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[ ] Grade A: Priority Publishing	Google Search:	[ ] Accept
[ ] Grade B (Very good)	[Y] Grade B: minor language polishing	[ ] Existed	[Y] High priority for publication
[Y] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	
[ ] Grade D (Fair)		BPG Search:	[ ]Rejection
[ ] Grade E (Poor)	[ ] Grade D: rejected	[ ] Existed	[ ] Minor revision
		[ ] No records	[ ] Major revision

COMMENTS TO AUTHORS

Review comments on "8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via down-regulation of β-catenin" submitted by Quan MF, et al. to World Journal of Gastroenterology. General comments: This manuscript concludes that 8-bromo-7-methoxychrysin (BrMC) can inhibit the functions and characteristics of liver cancer stem cells (LCSCs) derived from liver cancer MHCC97 cell line through down-regulation of β-catenin expression. I think it is a good research with necessary information. However, I hope the authors can pay attentions to the following: 1.Is it the right name for "Shanghai Xiangf Biotechnology Co., Ltd." ? 2.It is not necessary to discuss the results in the Results, which you may leave in the Discussion. 3.Hope to add histological descriptions on the tumor model derived from LCSCs with immunohistological stains using stem cell markers. If so, I can make sure your conclusion is reasonable.